Skip to main content
Log in

An improved and robust scale-up process aided with identification and control of critical process impurities in darunavir ethanolate

  • Published:
Research on Chemical Intermediates Aims and scope Submit manuscript

Abstract

A robust and safe industrial process, including five isolations and drying steps for widely prescribed anti-HIV (protease inhibitor) drug darunavir ethanolate 2, has been developed. A salient feature of this process is the development of procedures enabling the efficient synthesis of multi-kilogram quantity of darunavir ethanolate, and process demonstrations through plant scale preparation are offered where darunavir molecule has been prepared with overall > 70% chemical yield and > 99.8% purity without involving any purification procedure(s), with all possible process impurities below than the desired limit (not more than 0.08%) were isolated, synthesized and characterized. The developed process is entirely robust, very efficient and demonstrated up to kilograms scale.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Scheme 1
Fig. 2

Similar content being viewed by others

Notes

  1. http://www.cancer.org/acs/groups/cid/documents/webcontent/002295-pdf.pdf.

  2. https://aidsinfo.nih.gov/education-materials/fact-sheets/21/58/fda-approved-hiv-medicines.

  3. http://emedicine.medscape.com/article/1533218-overview#a2.

  4. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065005.htm.

References

  1. J.E. Arts, J.D. Hazuda, Cold Spring Harb Perspect Med 2, a007161 (2012)

    Article  Google Scholar 

  2. M. Mahdi, Z. Szojka, J.A. Mótyán, J. Tozsér, Viruses 7, 6152 (2015)

    Article  CAS  Google Scholar 

  3. N. Kumarasamy, A. Patel, S. Pujari, Indian J. Med. Res. 134, 787 (2011)

    Article  CAS  Google Scholar 

  4. Centers for Disease Control and Prevention (2012, November 30). Vital signs: HIV infection, testing, and risk behaviors among youths - United States. Morbidity and Mortality Weekly Report (MMWR) 61(47), pp. 971–976

  5. M.R. Ghante, R.S. Shelar, S.D. Sawant, M.M. Kadam, Int. J. Pharm. Pharm. Sci. 6, 240 (2014)

    CAS  Google Scholar 

  6. M.L. Vazluez, R.A. Mueller, J.J. Talley, D.P. Getman, G.A. DeCrescenzo, J.N. Freskos, R.M. Heintz, D.E. Berternshaw, U.S. Patent RE 42,889 E, 2011

  7. A.N. Kobe, T.S. Akashi, H.M. Takasago, K.I. Kakogawa, N.Y. Matsubara, U.S. Patent 5,929,284, 1999

  8. N.M.F. Goyvaerts, P.T.B.P. Wigerinck, H.B. Zinser, B.M. Ebert, U.S. Patent 7,772,411 B2, 2010

  9. A.K. Ghosh; G.M. Bilcer, T. Devasamudram, U.S. Patent 7,897,635 B2, 2011

  10. P.T.B.P. Wigerinck, D.L.N.G. Surleraux, W.G. Verschueren, H.A. DeKock, W.A.A. Aelterman, U.S. Patent Appl. 2011/0160468 A1, 2011

  11. M. Mizhiritskii, E. Marom, U.S. Patent Appl. 2012/0296101 A1, 2012

  12. K.R. Babu, V.K. Rao, C.N. Raju, Der Pharma Chem. 3, 389 (2011)

    CAS  Google Scholar 

  13. A.K. Ghosh, S. Leshchenko, M. Noetzel, J. Org. Chem. 69, 7822 (2004)

    Article  CAS  Google Scholar 

  14. M.L. Vazluez, R.A. Mueller, J.J. Talley, D.P. Getman, G.A. DeCrescenzo, J.N. Freskos, R.M. Heintz, D.E. Berternshaw, U.S. Patent 6,248,775 B1, 2001

  15. Q.P.J.L. Mario, K.B.R. Romanie, V.R. Jan, L.C.S. Maria, K.J.H.M. Hero, L.F.A. Marie, Patent EP 1732931 B1, 2016

  16. H.W.P. Vermeersch, D.J.C.T. Thone, D.V. Marie-Louise, U.S. Patent 7,700,645 B2, 2010

  17. H. Singh, T.G. Varadaraju, S. Shah, S.R. Kola, P.K. Sahu, V.G. Regula, V.R. Rayavarpu, P. Kumar, S.K. Dubey, Indian Patent 2451/CHE/2014 A, 2016

  18. S.M. Kelly, B.H. Lipshutz, Org. Lett. 16, 98 (2014)

    Article  CAS  Google Scholar 

  19. D.C. Gowda, B. Mahesh, S. Gowda, Indian J. Chem. 40B, 55 (2001)

    Google Scholar 

  20. D.C. Gowda, S. Gowda, Indian J. Chem. 42B, 180 (2003)

    CAS  Google Scholar 

  21. H. Chen, C.N. Nilsen, A. Choudhury, K.L. Sorgi, Arkivoc 14, 1 (2008)

    Google Scholar 

  22. J.A. Mangravite, J. Chem. Educ. 60, 439 (1983)

    Article  CAS  Google Scholar 

  23. D.C. Gowda, S. Gowda, Indian J. Chem. 39B, 70 (2000)

    Google Scholar 

  24. H.D. Burge, D.J. Collins, Ind. Eng. Chem. Prod. Dev. 19, 389 (1980)

    Article  CAS  Google Scholar 

  25. I. Pogorelic, M. Filipan- Litvic, S. Merkas, G. Ljubic, I. Cepanec, M. Litvic, J. Mol. Catal. A: Chem. 274, 202 (2007)

    Article  CAS  Google Scholar 

  26. M. Srinivasan, A. Yurek-George, A. Ganesan, Mol. Divers. 9, 291 (2005)

    Article  CAS  Google Scholar 

  27. A. Isidro- Llobet, M. Alvarez, F. Albericio, Chem. Rev. 109, 2455 (2009)

    Article  CAS  Google Scholar 

  28. D.S. Coffey, M.N. Hawk, S.W. Pedersen, S.J. Ghera, P.G. Marler, P.N. Dodson, M.L. Lytle, Org. Process Res. Dev. 8, 945 (2004)

    Article  CAS  Google Scholar 

  29. M. Mizhiritskii, E. Marom, U.S. Patent Appl. 20120296101 A1, 2012

  30. V. Ahire, S. Sasne, A. Deshmukh, K. Kumbhar, A. Bhatnagar, D. Verma, R. Vyas, G. Singh, N. Bhise, U.S. Patent Appl. 20120237770 A1, 2012

  31. P. Kar, R. Lipowsky, V. Knecht, J. Phys. Chem. B. 117, 5793 (2013)

    Article  CAS  Google Scholar 

  32. E. Marom, U.S. Patent Appl. 20120035142 A1, 2012

  33. M. Chen, Family Health International Biostatistics Workshop (New Delhi, India, 2007)

Download references

Acknowledgements

The authors greatly appreciate financial support for this work from Micro Labs Ltd., API Division Centre, ML-27, Bangalore. We thank our group colleagues for their appreciated contribution. The Analytical Department of Micro Labs Limited acknowledged for providing support for analytical and spectral data.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Harnam Singh or Pramod Kumar.

Ethics declarations

Conflict of interest

The authors declared that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 1848 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Girigani, S., Singh, H., Kola, S.R. et al. An improved and robust scale-up process aided with identification and control of critical process impurities in darunavir ethanolate. Res Chem Intermed 46, 267–281 (2020). https://doi.org/10.1007/s11164-019-03948-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11164-019-03948-4

Keywords

Navigation